ImageneBio Reports Third Quarter 2026 Financial Results
Lower quarterly expenses accompanied a narrower loss, while nine-month general and administrative costs increased.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ImageneBio (IMA) reported a narrower third-quarter 2026 net loss while advancing its olevaprubart clinical program for inflammatory diseases. Net loss was $15.620 million, versus $24.779 million a year earlier; basic and diluted loss per common share narrowed to $0.91 from $2.91. Research and development expenses fell to $11.270 million, while general and administrative expenses declined to $6.039 million.
Cash, cash equivalents and marketable securities totaled $126.6 million at September 30, 2026. ImageneBio expects funding to support planned operations into the first quarter of 2028. The company anticipates Phase 2b ADAPTIVE topline data in atopic dermatitis in the fourth quarter of 2027 and plans to initiate a Phase 2 alopecia areata study by year-end 2026, with initial data expected in 2028. No cases of Kaposi sarcoma have been observed to date across its clinical trials.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter net loss narrowed to $15.620 million from $24.779 million a year earlier.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Liquidity of $126.6 million is expected to fund planned operations into the first quarter of 2028.
- Moderate point. Forward-looking: it has not happened yet and may not happen.ADAPTIVE and its long-term extension are progressing as planned; topline ADAPTIVE data is anticipated in fourth-quarter 2027.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Alopecia areata Phase 2 initiation remains on track for year-end 2026; initial data is expected in 2028.
- Minor pointThird-quarter basic and diluted loss per common share narrowed to $0.91 from $2.91 a year earlier.
12 minor points
- Minor pointThird-quarter research and development expenses fell to $11.270 million from $15.156 million a year earlier.
- Minor pointThird-quarter general and administrative expenses fell to $6.039 million from $11.036 million a year earlier.
- Minor pointNo Kaposi sarcoma cases have been observed to date across all clinical trials.
- Minor pointAlopecia areata exploratory findings showed recovery of hair and follicle-associated genes at the scalp with olevaprubart treatment.
- Minor pointAlopecia areata findings showed no statistically significant OX40 changes indicating cell depletion and no widespread immune function disruption.
- Minor pointNine-month net loss narrowed to $36.417 million from $38.441 million in the comparable 2025 period.
- Minor pointNine-month basic and diluted loss per common share narrowed to $2.45 from $9.98 in 2025.
- Minor pointNine-month research and development expenses fell to $23.900 million from $24.849 million in 2025.
- Minor pointThird-quarter net interest income rose to $1.189 million from $1.055 million a year earlier.
- Minor pointNine-month net interest income rose to $3.566 million from $0.742 million in 2025.
- Minor pointThird-quarter other income, net, rose to $0.520 million from $0.284 million a year earlier.
- Minor pointNine-month other income, net, rose to $1.235 million from $0.288 million in 2025.
Negative
- Moderate pointNine-month operating loss widened to $41.172 million from $39.545 million in 2025.
- Moderate pointVoting common shares outstanding increased to 12,456,281 at September 30, 2026, from 10,650,925 at December 31, 2025.
- Minor pointNine-month general and administrative expenses increased to $17.272 million from $15.496 million in 2025.
- Minor pointNine-month license revenue fell to zero from $0.800 million in 2025.
- Minor pointStockholders’ equity declined to $128.138 million at September 30, 2026, from $133.139 million at December 31, 2025.
News Explained
At
Key Figures
- Cash, equivalents and marketable securities
- $126.6 million
- As of September 30, 2026
- Planned operations funding horizon
- Into the first quarter of 2028
- Company's expectation based on available resources
- R&D expenses
- $11.3 million vs. $15.2 million
- Three months ended September 30, 2026 vs. same period in 2025
- G&A expenses
- $6.0 million vs. $11.0 million
- Three months ended September 30, 2026 vs. same period in 2025
- Net loss
- $15.6 million vs. $24.8 million
- Three months ended September 30, 2026 vs. same period in 2025
- Net loss per share
- $0.91 vs. $2.91
- Basic and diluted; three months ended September 30, 2026 vs. same period in 2025
- ADAPTIVE topline data
- Fourth quarter of 2027
- Phase 2b atopic dermatitis trial
- Alopecia areata Phase 2 study initiation
- By the end of 2026
- Olevaprubart study
Previous Earnings Reports
-
Reported $136.2 million cash, Q1 2028 runway and Q4 2027 ADAPTIVE topline timing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adcc medical
pharmacokinetics medical
monoclonal antibody medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the quarter ended September 30, 2026, and provided a company update.
Company Highlights
- Olevaprubart, also known as IMG-007, a potential first-in-class therapeutic targeting the OX40 pathway, is a non-T cell-depleting, ADCC-silenced, anti-OX40 receptor antagonist with an extended half-life.
- The Phase 2b ADAPTIVE trial and the long-term extension (LTE) study of olevaprubart in moderate-to-severe atopic dermatitis (AD) continue to progress as planned.
- A Phase 2 study in alopecia areata (AA) is on track to initiate by the end of this year.
- No cases of Kaposi sarcoma have been observed to date across all clinical trials.
- As of September 30, 2026, the Company held
$126.6 million in cash, cash equivalents and marketable securities, providing anticipated funding for planned operations into the first quarter of 2028.
“We are advancing our trials, developing a robust data set that we believe could demonstrate olevaprubart’s disease-modifying potential and tolerability profile across inflammatory indications. Our safety database continues to grow as we progress, and we are gaining experience across biologic- and JAK-experienced patients as well as those that are naïve to advanced therapies,” Kristin Yarema, Ph.D., chief executive officer of Imagene, commented. “With ADAPTIVE on course for topline data in the fourth quarter of 2027 and our alopecia areata trial on track to begin by year end, we are executing with capital discipline, and we are poised to deliver data that could demonstrate the true value potential of oleva.”
Olevaprubart Program Updates
- Atopic Dermatitis: The Phase 2b ADAPTIVE trial continues to progress as planned under the amended protocol. Topline data from the study is anticipated in the fourth quarter of 2027.
- The LTE study for patients who have completed one year in ADAPTIVE also continues to progress as planned.
- Alopecia Areata: Imagene is on track to initiate a Phase 2 study of olevaprubart in alopecia areata by the end of 2026.
- Initial data is expected in 2028, leveraging the clinical operations and investigator network the Company has developed through its AD program and AA proof-of-concept trial.
- Scientific Presentations: Imagene presented two posters on olevaprubart at the 2026 European Academy of Dermatology and Venereology (EADV) Congress highlighting olevaprubart’s profile.
- Title: Olevaprubart (IMG-007), a non-depleting anti-OX40 mAb: Exploratory biomarker insights into T cell phenotypic modulation from a proof-of-concept study in alopecia areata
- In the AA proof-of-concept study, recovery of hair and follicle-associated genes at the scalp was seen with olevaprubart treatment.
- There were no statistically significant changes found in peripheral or scalp measures of OX40 that would indicate depletion of OX40+ cells in AA patients who received olevaprubart, and no widespread immune function disruption. These results are consistent with the non-depleting nature of olevaprubart.
- Title: Olevaprubart (IMG-007), a non-depleting OX40 mAb: Optimizing peak loading concentration and exposure range to unlock the full potential of OX40-OX40L pathway targeting immune-mediated diseases
- The data describes olevaprubart’s pharmacokinetics as well as the rationale for and approach to optimization of olevaprubart exposure in the Phase 2b ADAPTIVE trial.
- The data describes olevaprubart’s pharmacokinetics as well as the rationale for and approach to optimization of olevaprubart exposure in the Phase 2b ADAPTIVE trial.
- Title: Olevaprubart (IMG-007), a non-depleting anti-OX40 mAb: Exploratory biomarker insights into T cell phenotypic modulation from a proof-of-concept study in alopecia areata
Third Quarter 2026 Financial Highlights
Cash Position: The Company ended September 30, 2026, with
Research and Development (R&D) Expenses: R&D expenses were
General and Administrative (G&A) Expenses: G&A expenses were
Net Loss: Net loss was
About Olevaprubart
Olevaprubart is an investigational, non-T cell-depleting monoclonal antibody targeting OX40, a receptor protein primarily found on activated human T cells. When OX40 binds its ligand OX40L in human tissue, the signal generated plays a key role in the activation, expansion, and survival of many subtypes of T cells. Targeted inhibition of OX40 is being studied in the clinic across a range of autoimmune, inflammatory, and immunological conditions where aberrant signaling of one or more T cell subtypes is believed to drive disease. Olevaprubart has been engineered to include a silenced antibody-dependent cell-mediated cytotoxicity function demonstrated to avoid T cell depletion or killing and intended to minimize safety risk. This technology also resulted in an approximately 5-week half-life, prolonging therapeutic activity with the aim of maximizing time between doses for a patient.
About ImageneBio, Inc.
Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company’s program, olevaprubart, is a receptor-targeting, non-depleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of olevaprubart in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of olevaprubart in patients with moderate-to-severe atopic dermatitis. For more information, please visit www.imagenebio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the expected timing, progress and results of the Company's ongoing Phase 2b ADAPTIVE trial and long-term extension study; the anticipated benefits and potential impact of the amended ADAPTIVE trial protocol; the expected timing of initiation of the Company's Phase 2 alopecia areata trial and the timing of initial clinical data; the therapeutic potential, safety profile and clinical differentiation of olevaprubart; the Company's plans to advance the development of olevaprubart across multiple inflammatory and autoimmune indications; the Company's expected cash resources, capital requirements and financing plans; and other statements regarding management's intentions, plans, beliefs, expectations or forecasts for the future. Words such as “will,” “can,” “expect,” “may,” “plan,” “potential,” “goal,” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: risks associated with the nonclinical and clinical development and regulatory approval of olevaprubart, including potential delays in the completion of clinical trials and potential safety and other complications thereof; the timing of the availability of data from the Company's clinical trials; the risk that interim, topline and preliminary data from the Company’s preclinical studies or clinical trials that are announced or published from time to time may not be predictive of future results and may change as more patient data become available and are subject to audit and verification procedures, which could result in material changes to the final data; the risk that competitor data may materially and adversely impact the Company, its business, and its future prospects; the clinical utility, potential differentiation and/or benefits and market acceptance of olevaprubart; the requirement for additional capital to continue to advance the olevaprubart program, which may not be available on favorable terms or at all; the Company's ability to attract, hire, and retain skilled executive officers and employees; the Company's ability to protect its intellectual property and proprietary technologies; the Company's reliance on third parties, contract manufacturers, and contract research organizations; the possibility that the Company may be adversely affected by other economic, political, business, or competitive factors; and risks associated with changes in applicable laws or regulations or government resources and policies. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in the Company's filings with the Securities and Exchange Commission (the “SEC”), including the risks set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the Company’s subsequent Quarterly Reports on Form 10-Q, filed with the SEC, and in the Company’s other filings with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
| IMAGENEBIO, INC. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (Unaudited) | ||||||||
| (In thousands, except share and per share amounts) | ||||||||
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 84,853 | $ | 94,532 | ||||
| Marketable securities | 41,744 | 40,817 | ||||||
| Prepaid expenses and other current assets | 4,000 | 4,939 | ||||||
| Total current assets | 130,597 | 140,288 | ||||||
| Operating lease right-of-use assets, net | 345 | 790 | ||||||
| Deposits and other non-current assets | 6,119 | 4,878 | ||||||
| Promissory note receivable from related party | 5,480 | 7,020 | ||||||
| Total assets | $ | 142,541 | $ | 152,976 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 931 | $ | 1,439 | ||||
| Accrued expenses and other current liabilities | 5,832 | 7,533 | ||||||
| Operating lease liabilities, current | 1,312 | 2,262 | ||||||
| Total current liabilities | 8,075 | 11,234 | ||||||
| Operating lease liabilities, non-current | — | 713 | ||||||
| Other non-current liabilities | 848 | 870 | ||||||
| CVR liability due to related party | 5,480 | 7,020 | ||||||
| Total liabilities | 14,403 | 19,837 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred Stock, | — | — | ||||||
| Voting Common Stock, | 12 | 11 | ||||||
| Non-Voting Common Stock, | — | — | ||||||
| Additional paid-in capital | 394,766 | 363,094 | ||||||
| Accumulated other comprehensive income (loss) | (170 | ) | 87 | |||||
| Accumulated deficit | (266,470 | ) | (230,053 | ) | ||||
| Total stockholders’ equity | 128,138 | 133,139 | ||||||
| Total liabilities and stockholders’ equity | $ | 142,541 | $ | 152,976 | ||||
| IMAGENEBIO, INC. | ||||||||||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| License revenue | $ | — | $ | — | $ | — | $ | 800 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 11,270 | 15,156 | 23,900 | 24,849 | ||||||||||||
| General and administrative | 6,039 | 11,036 | 17,272 | 15,496 | ||||||||||||
| Total operating expenses | 17,309 | 26,192 | 41,172 | 40,345 | ||||||||||||
| Loss from operations | (17,309 | ) | (26,192 | ) | (41,172 | ) | (39,545 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income, net | 1,189 | 1,055 | 3,566 | 742 | ||||||||||||
| Other income, net | 520 | 284 | 1,235 | 288 | ||||||||||||
| Total other income, net | 1,709 | 1,339 | 4,801 | 1,030 | ||||||||||||
| Loss before income taxes | (15,600 | ) | (24,853 | ) | (36,371 | ) | (38,515 | ) | ||||||||
| Income tax expense (benefit) | 20 | (74 | ) | 46 | (74 | ) | ||||||||||
| Net loss | (15,620 | ) | (24,779 | ) | (36,417 | ) | (38,441 | ) | ||||||||
| Accretion of redeemable convertible preferred shares | — | (846 | ) | — | (7,046 | ) | ||||||||||
| Net loss attributable to common stockholders | $ | (15,620 | ) | $ | (25,625 | ) | $ | (36,417 | ) | $ | (45,487 | ) | ||||
| Net loss per common share, basic and diluted | $ | (0.91 | ) | $ | (2.91 | ) | $ | (2.45 | ) | $ | (9.98 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 17,122,691 | 8,797,126 | 14,853,552 | 4,559,574 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (15,620 | ) | $ | (24,779 | ) | $ | (36,417 | ) | $ | (38,441 | ) | ||||
| Other comprehensive loss: | ||||||||||||||||
| Unrealized gain (loss) on marketable securities | (119 | ) | 94 | (257 | ) | 94 | ||||||||||
| Foreign currency translation adjustment | — | (3 | ) | — | (29 | ) | ||||||||||
| Total comprehensive loss | $ | (15,739 | ) | $ | (24,688 | ) | $ | (36,674 | ) | $ | (38,376 | ) | ||||
Contacts
Investor Contact:
Rebecca Cohen
rcohen@imagenebio.com
Media Contact:
Jason Braco, PhD
Valence Communications
jason@valencecomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were ImageneBio's third-quarter 2026 financial results?
ImageneBio reported a $15.620 million net loss for the quarter ended September 30, 2026, compared with $24.779 million a year earlier. Basic and diluted loss per common share narrowed to $0.91 from $2.91. Research and development expenses were $11.270 million, and general and administrative expenses were $6.039 million.
When does ImageneBio expect its next olevaprubart clinical milestones?
ImageneBio anticipates ADAPTIVE topline data in the fourth quarter of 2027 and plans to initiate its Phase 2 alopecia areata study by the end of 2026. Initial data from the alopecia areata study is expected in 2028.
Who can enter ImageneBio's ADAPTIVE long-term extension study?
The long-term extension study is for patients who have completed one year in ADAPTIVE. The extension study continues to progress as planned.